The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF
The company delivered revenues of Rs. 5,554 crore, representing 10% growth in FY25
The new facility combines advanced technology, enhanced capacity, and holistic care, reaffirming HCG’s commitment to accessible, world-class oncology in Gujarat
DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care
Access to NIPT, TB and Rare Disease diagnostics to benefit thousands of patients nationwide
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
Subscribe To Our Newsletter & Stay Updated
